PCSK9 and COVID-19: Recent results from a pilot trial testing the ‘Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19’ (IMPACT-SIRIO 5; NCT04941105) demonstrate a survival benefit among adult patients.27 It is conceivable that such therapies will be trialed in other critically ill cohorts including sepsis and acute respiratory distress syndrome.